

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")



29 March 2018

Chief Executive Officer succession and other changes to the composition of the Board and its Committees

Mediclinic, a leading international private healthcare services group, announces that Dr Ronnie van der Merwe (Chief Clinical Officer and Chief Executive Officer ("CEO") Designate) will succeed Danie Meintjes as CEO of the Company on 1 June 2018 and will be appointed as an Executive Director of the Company with effect from that date. This follows on from the previous announcements made regarding Mr Meintjes' intention to retire as CEO by 31 July 2018 (published on 25 July 2017) and the subsequent announcement of Dr Van der Merwe being designated as his successor (published on 27 November 2017). Dr Van der Merwe will also become a member of the Clinical Performance and Sustainability and Investment Committees with effect from 1 June 2018.

Mr Meintjes will remain an Executive Director of the Company until the conclusion of the Company's Annual General Meeting ("AGM") to be held on 25 July 2018.

The Board has also agreed to certain other changes to the Board and its Committees. Dr Felicity Harvey will take over from Dr Edwin Hertzog as Chair of the Clinical Performance and Sustainability Committee and Dr Muhadditha Al Hashimi will join the Committee as an additional member, both with effect from 1 April 2018. Dr Hertzog will remain a member of the Committee.

In addition, Ms Nandi Mandela and Prof Dr Robert Leu will retire as Non-executive Directors of the Company at the conclusion of the AGM. They will also retire from all relevant Board Committees at that time and further appointments will be made to those committees in due course.

Mediclinic's Chairman, Dr Edwin Hertzog commented:

"On behalf of my colleagues on the Board, I would like to thank Nandi and Robert for their commitment and valued contributions to the Board and the Group – in Robert's case during 25 years, firstly as a Director of Hirslanden AG, then Mediclinic International Limited and since 2016, as a Director of Mediclinic International plc. We are using the opportunity afforded by their retirement to further refresh the Board. In the meantime, we welcome Felicity's appointment as Chair of the Clinical Performance and Sustainability Committee and Muhadditha becoming a member of that Committee."

NOTES TO EDITORS

About Dr Ronnie van der Merwe

Dr Van der Merwe (aged 55) joined Mediclinic in 1999 and has been a member of the Group's Executive Committee since 2008. He established and built up the Clinical Information, Advanced Analytics, Health Information Management and Clinical Services functions at

Mediclinic and has been Group Chief Clinical Officer since 2007. He was appointed as a director of Mediclinic International Limited in 2010 up to the combination of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in February 2016. Until recent, he was a member of the Board of Directors at Wits Donald Gordon Medical Centre (Pty) Ltd and Chairman of the Board of Trustees for the Remedi Medical Aid Scheme (Remgro Limited's in-house medical scheme).

Dr Van der Merwe obtained qualifications in Advanced Management (Harvard Business School, USA), a Fellowship in Anaesthesia (College of Anaesthesiologists, South Africa) where he was the recipient of the Jack Abelsohn Medal, and a Bachelor of Medicine and Bachelor of Surgery (University of Stellenbosch, South Africa).

About Danie Meintjes

Mr Meintjes (aged 61) joined the group in 1985 as the Hospital Manager of Mediclinic Sandton before being appointed head of Human Resources and Training for Mediclinic as a whole. He subsequently became a member of Mediclinic International Limited's Executive Committee in 1995 and a director in 1996. Seconded to the company's operations in Dubai in 2006 and appointed as the Chief Executive Officer of Mediclinic Middle East in 2007, he was named Chief Executive Officer of Mediclinic International Limited in 2010. Following the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited, Mr Meintjes continued to serve as the Chief Executive Officer of the enlarged group since February 2016.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 29 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.

The divisions' contributions to Group revenue for the financial year ended 31 March 2017 were 48% by Hirslanden, 28% by Mediclinic Southern Africa and 24% by Mediclinic Middle East.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott – UK

+44 (0)20 3727 1000

Sherryn Schooling – South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd